Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1265-1273

  Meeuwisse, Cees M ^a   Van Der Linden, Michael P ^b   Rullmann, Ton A ^a   Allaart, Cornelia F ^b   Nelissen, Rob ^a   Huizinga, Tom W ^b   Garritsen, Anja ^a   Toes, René E ^b   Van Schaik, René ^a   Van Der Helm Van Mil, Annette H ^b  

^a Merck Sharp and Dohme   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ANGIOPOIETIN 2; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INFLIXIMAB; N TELOPEPTIDE OF TYPE I COLLAGEN; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; COMPUTER MODEL; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; JOINT DESTRUCTION; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BIOLOGICAL MARKERS; CHEMOKINE CXCL13; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; MALE; MIDDLE AGED; MODELS, ANATOMIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 79955564865     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30273     Document Type: Article

References (34)

1. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44: 1736-43. (Pubitemid 32758218)
2. Van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
3. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
4. De Vries-Bouwstra J, le Cessie S, Allaart C, Breedveld F, Huizinga T,. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J Rheumatol 2006; 33: 1747-53. (Pubitemid 44373205)
5. Visser K, Goekoop-Ruiterman Y, de Vries-Bouwstra J, Ronday K, Seys P, Kerstens P, et al. A matrix risk model for prediction of rapid radiographic progression in rheumatoid arthritis patients receiving different dynamic treatment strategies [abstract]. Ann Rheum Dis 2009; 68 Suppl III: iii402.
6. Vastesaeger N, Xu S, Aletaha D, St.Clair EW, Smolen J,. Matrix risk model for prediction of rapid radiographic progression in rheumatoid arthritis [abstract]. Ann Rheum Dis 2008; 67 Suppl II: ii63.
7. Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-7. (Pubitemid 43877926)
8. Tchetverikov I, Huizinga TW, van der Helm-van Mil AH,. Biomarkers in the prediction of radiographic progression in early rheumatoid arthritis: comment on the article by Young-Min et al [letter]. Arthritis Rheum 2008; 58: 1558-9. (Pubitemid 351705954)
9. Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009; 36: 1769-84.
10. Defranoux NA, Stokes CL, Young DL, Kahn AJ,. In silico modeling and simulation of bone biology: a proposal. J Bone Miner Res 2005; 20: 1079-84. (Pubitemid 40863795)
11. Rullmann JA, Struemper H, Defranoux NA, Ramanujan S, Meeuwisse CM, van Elsas A,. Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst Biol (Stevenage) 2005; 152: 256-62. (Pubitemid 43125144)
12. The RA PhysioLab platform and the Virtual Patient concept. 2010. URL:.
13. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB,. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8. (Pubitemid 19123055)
14. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90. (Pubitemid 41612204)
15. Van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 914-21.
16. Van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC,. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003; 21: S100-5. (Pubitemid 37265597)
17. Van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2242-7.
18. Van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009; 60: 2262-71.
19. Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30: 468-73. (Pubitemid 36301936)
20. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK,. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-45. (Pubitemid 30413866)
21. Lewis AK, Paterson T, Leong CC, Defranoux N, Holgate ST, Stokes CL,. The roles of cells and mediators in a computer model of chronic asthma. Int Arch Allergy Immunol 2001; 124: 282-6. (Pubitemid 32304826)
22. Kansal AR, Trimmer J,. Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. Syst Biol (Stevenage) 2005; 152: 214-20. (Pubitemid 43125139)
23. Powell LM, Lo A, Cole MS, Trimmer J,. Application of predictive biosimulation to the study of atherosclerosis: development of the cardiovascular PhysioLab platform and evaluation of CETP inhibitor therapy. Proceedings of the Foundations of Engineering in Systems Biology (FOSBE)2007; 2007 Sept. 9-12; Stuttgart, Germany.
24. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58: 2257-67.
25. Rioja-Pastor I, Dickson MC, Binks MH, Lukey PT, Petavy F, McClinton C, et al. B-lymphocyte chemoattractant (BLC/CXCL13): a potential novel disease activity marker of rheumatoid arthritis [abstract]. Ann Rheum Dis 2007; 66 Suppl II: ii452.
26. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167: 1072-80. (Pubitemid 32660867)
27. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001; 166: 650-5. (Pubitemid 32038489)
28. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192: 1545-52.
29. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B,. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192: 1553-62.
30. + T cells. J Exp Med 2001; 193: 1373-81. (Pubitemid 32565966)
31. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B,. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998; 187: 655-60. (Pubitemid 28093368)
32. Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and β-N-acetylhexosaminidase release. J Cell Physiol 2003; 194: 71-9. (Pubitemid 35424229)
33. Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009; 36: 1785-91.
34. Maksymowych WP, FitzGerald O, Wells GA, Gladman DD, Landewe R, Ostergaard M, et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009; 36: 1792-9.